
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1806225/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Realâ€World Six―and Twelveâ€Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries. Arthritis Care and Research, 2022, 74, 1205-1218.	1.5	20
2	Current differentiation between radiographic and non-radiographic axial spondyloarthritis is of limited benefit for prediction of important clinical outcomes: data from a large, prospective, observational cohort. RMD Open, 2022, 8, e002067.	1.8	11
3	The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis. Rheumatology, 2022, 61, 4741-4751.	0.9	6
4	Trajectories of humoral and cellular immunity and responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy. RMD Open, 2022, 8, e002166.	1.8	15
5	Does tenosynovitis of the hand detected by B-mode ultrasound predict loss of clinical remission in rheumatoid arthritis? Results from a real-life cohort. Journal of Ultrasonography: Official Publication of Polish Ultrasound Society / Red Nacz Iwona SudoÅ,-SzopiÁ,,ska, 2022, 22, 21-27.	0.7	1
6	Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy. Rheumatology, 2022, 62, 89-97.	0.9	13
7	Tumor Necrosis Factor Inhibitor Monotherapy Versus Combination Therapy for the Treatment of Psoriatic Arthritis: Combined Analysis of European Biologics Databases. Journal of Rheumatology, 2021, 48, 48-57.	1.0	7
8	Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort. Annals of the Rheumatic Diseases, 2021, 80, 238-241.	0.5	54
9	Associations between serum antibodies to periodontal pathogens and preclinical phases of rheumatoid arthritis. Rheumatology, 2021, 60, 4755-4764.	0.9	13
10	Thymic Hyperplasia with Lymphoepithelial Sialadenitis (LESA)-Like Features: Strong Association with Lymphomas and Non-Myasthenic Autoimmune Diseases. Cancers, 2021, 13, 315.	1.7	7
11	Predictive value of anti-CarP and anti-PAD3 antibodies alone or in combination with RF and ACPA for the severity of rheumatoid arthritis. Rheumatology, 2021, 60, 4598-4608.	0.9	15
12	Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration. Annals of the Rheumatic Diseases, 2021, 80, 1410-1418.	0.5	28
13	Site-specific resolution of enthesitis in patients with axial spondyloarthritis treated with tumor necrosis factor inhibitors. Arthritis Research and Therapy, 2021, 23, 165.	1.6	2
14	Comparison of Psoriatic Arthritis and Rheumatoid Arthritis Patients across Body Mass Index Categories in Switzerland. Journal of Clinical Medicine, 2021, 10, 3194.	1.0	8
15	Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study. Lancet Rheumatology, The, 2021, 3, e789-e797.	2.2	179
16	Treatment of severe periodontitis may improve clinical disease activity in otherwise treatment-refractory rheumatoid arthritis patients. Rheumatology, 2020, 59, 243-245.	0.9	8
17	Effect of rheumatoid arthritis and age on metacarpal bone shaft geometry and density: A longitudinal pQCT study in postmenopausal women. Seminars in Arthritis and Rheumatism, 2020, 50, 220-227.	1.6	7
18	Discordances between clinical and ultrasound measurements of disease activity among RA patients followed in real life. Joint Bone Spine, 2020, 87, 57-62.	0.8	3

#	Article	IF	CITATIONS
19	Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment—results from 12 countries in EuroSpA. Rheumatology, 2020, 59, 1640-1650.	0.9	18
20	Synovitis in rheumatoid arthritis detected by grey scale ultrasound predicts the development of erosions over the next three years. Rheumatology, 2020, 59, 1556-1565.	0.9	9
21	Infectious Triggers in Periodontitis and the Gut in Rheumatoid Arthritis (RA): A Complex Story About Association and Causality. Frontiers in Immunology, 2020, 11, 1108.	2.2	34
22	Spinal radiographic progression in axial spondyloarthritis and the impact of classification as nonradiographic versus radiographic disease: Data from the Swiss Clinical Quality Management cohort. PLoS ONE, 2020, 15, e0230268.	1.1	17
23	Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort. Annals of the Rheumatic Diseases, 2020, 79, 1203-1209.	0.5	37
24	Citrullination in periodontium is associated with Porphyromonas gingivalis. Archives of Oral Biology, 2020, 114, 104695.	0.8	13
25	Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis. PLoS ONE, 2019, 14, e0216746.	1.1	7
26	Fluorescence Lifetimes in Patients With Hydroxychloroquine Retinopathy. , 2019, 60, 2165.		16
27	The links of hepcidin and erythropoietin in the interplay of inflammation and iron deficiency in a large observational study of rheumatoid arthritis. British Journal of Haematology, 2019, 186, 101-112.	1.2	6
28	Expression of human and Porphyromonas gingivalis glutaminyl cyclases in periodontitis and rheumatoid arthritis–A pilot study. Archives of Oral Biology, 2019, 97, 223-230.	0.8	19
29	Can Ultrasound Be Used to Predict Loss of Remission in Patients with RA in a Real-life Setting? A Multicenter Cohort Study. Journal of Rheumatology, 2018, 45, 887-894.	1.0	14
30	Low Hemoglobin and Radiographic Damage Progression in Early Rheumatoid Arthritis: Secondary Analysis From a Phase <scp>III</scp> Trial. Arthritis Care and Research, 2018, 70, 861-868.	1.5	17
31	The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritis. Clinical Rheumatology, 2017, 36, 677-682.	1.0	20
32	Hypothesis-free analyses from a large psoriatic arthritis cohort support merger to consolidated peripheral arthritis definition without subtyping. Clinical Rheumatology, 2017, 36, 2035-2043.	1.0	8
33	Skin Manifestations of Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, and Spondyloarthritides. Clinical Reviews in Allergy and Immunology, 2017, 53, 371-393.	2.9	52
34	Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritis. Rheumatology, 2017, 56, 1579-1585.	0.9	63
35	Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis. Arthritis Research and Therapy, 2017, 19, 164.	1.6	69
36	Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK). Arthritis Research and Therapy, 2016, 18, 88.	1.6	5

#	Article	IF	CITATIONS
37	Citrullination in the periodontium—a possible link between periodontitis and rheumatoid arthritis. Clinical Oral Investigations, 2016, 20, 675-683.	1.4	80
38	The Dermatologists' Role in Managing Psoriatic Arthritis: Results of a Swiss Delphi Exercise Intended to Improve Collaboration with Rheumatologists. Dermatology, 2015, 230, 75-81.	0.9	13
39	Chronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort study. Annals of the Rheumatic Diseases, 2015, 74, 718-723.	0.5	72
40	Ultrasound evaluation of synovitis in RA: Correlation with clinical disease activity and sensitivity to change in an observational cohort study. Joint Bone Spine, 2014, 81, 222-227.	0.8	29
41	Anaemia may add information to standardised disease activity assessment to predict radiographic damage in rheumatoid arthritis: a prospective cohort study. Annals of the Rheumatic Diseases, 2014, 73, 691-696.	0.5	41
42	Persistence of ultrasound synovitis in patients with rheumatoid arthritis fulfilling the DAS28 and/or the new ACR/EULAR RA remission definitions: Results of an observational cohort study. Joint Bone Spine, 2014, 81, 426-432.	0.8	43
43	Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists. Annals of the Rheumatic Diseases, 2012, 71, 1680.2-1685.	0.5	16
44	New Biologic Drugs: Anti-Interleukin Therapy. Developments in Ophthalmology, 2012, 51, 79-89.	0.1	1
45	Biologics in rheumatoid arthritis - recommendations for Swiss practice. Swiss Medical Weekly, 2011, 141, w13189.	0.8	4
46	Abnormal bone geometry at the metacarpal bone shaft of rheumatoid arthritis patients with maintained muscle-bone relationship. Arthritis Care and Research, 2010, 63, n/a-n/a.	1.5	11
47	Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?. Annals of the Rheumatic Diseases, 2010, 69, 387-393.	0.5	145
48	Reduced trabecular bone mineral density and cortical thickness accompanied by increased outer bone circumference in metacarpal bone of rheumatoid arthritis patients: a cross-sectional study. Arthritis Research and Therapy, 2010, 12, R119.	1.6	29
49	Hepatoprotective effect of tumour necrosis factor α blockade in psoriatic arthritis: a cross-sectional study. Annals of the Rheumatic Diseases, 2010, 69, 1148-1150.	0.5	34
50	Swiss Consensus Statement: Recommendations for optimising re-treatment with MabThera® (rituximab) in rheumatoid arthritis. Swiss Medical Weekly, 2010, 140, w13073.	0.8	9
51	High-resolution ultrasound confirms reduced synovial hyperplasia following rituximab treatment in rheumatoid arthritis. Rheumatology, 2009, 48, 939-943.	0.9	21
52	Measuring finger joint cartilage by ultrasound as a promising alternative to conventional radiograph imaging. Arthritis and Rheumatism, 2009, 61, 435-441.	6.7	81
53	Induction of complete and sustained remission of rheumatoid pachymeningitis by rituximab. Arthritis and Rheumatism, 2009, 60, 1632-1634.	6.7	32
54	Class-switched B cells display response to therapeutic B cell depletion in rheumatoid arthritis. Arthritis Research and Therapy, 2009, 11, R62.	1.6	47

#	Article	IF	CITATIONS
55	Novel screening tools for latent tuberculosis: time to leave an old friend?. Current Opinion in Rheumatology, 2009, 21, 238-243.	2.0	9
56	Soluble tumour necrosis factor receptors sTNFR1 and sTNFR2 are produced at sites of inflammation and are markers of arthritis activity in Behçet's disease. Scandinavian Journal of Rheumatology, 2008, 37, 135-141.	0.6	29
57	Pregnancy induces numerical and functional changes of CD4+CD25high regulatory T cells in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2008, 67, 984-990.	0.5	59
58	The -308 tumour necrosis factor-Â gene polymorphism predicts therapeutic response to TNFÂ-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology, 2007, 46, 93-96.	0.9	192
59	Genomic imprinting of insulin-like growth factor 2 (IGF-2) in chronic synovitis. Growth Hormone and IGF Research, 2007, 17, 500-505.	0.5	4
60	Class switched memory B cells are enriched in the synovium after rituximab treatment. Arthritis Research and Therapy, 2007, 9, P24.	1.6	0
61	Imbalance in distribution of functional autologous regulatory T cells in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2007, 66, 1151-1156.	0.5	58
62	B cell depletion may be more effective than switching to an alternative anti–tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti–tumor necrosis factor agents. Arthritis and Rheumatism, 2007, 56, 1417-1423.	6.7	192
63	Observational study of a patient and doctor directed pre-referral questionnaire for an early arthritis clinic. Rheumatology International, 2007, 28, 21-26.	1.5	10
64	Inhibition of IL-1, IL-6, and TNF-α in immune-mediated inflammatory diseases. Seminars in Immunopathology, 2006, 27, 391-408.	4.0	127
65	Disease association of two distinct interleukin-18 promoter polymorphisms in Caucasian rheumatoid arthritis patients. Genes and Immunity, 2005, 6, 211-216.	2.2	44
66	Correction of iron-deficient erythropoiesis in the treatment of anemia of chronic disease with recombinant human erythropoietin. Annals of Hematology, 2005, 84, 159-166.	0.8	42
67	Interleukin-18 receptor expression in synovial fluid-derived fibroblast-like synoviocytes: Comment on the article by Kawashima and Miossec. Arthritis and Rheumatism, 2004, 50, 2373-2374.	6.7	2
68	Expression of interleukin-18 receptor in fibroblast-like synoviocytes. Arthritis Research, 2002, 4, 139.	2.0	31
69	Prednisolone induces interleukin-18 expression in mononuclear blood and myeloid progenitor cells. Inflammation Research, 2002, 51, 457-463.	1.6	9
70	Folinic acid antagonizes methotrexate-induced differentiation of monocyte progenitors. Rheumatology International, 2002, 22, 60-67.	1.5	15
71	HLA-DRB1*04 subtypes are associated with increased inflammatory activity in early rheumatoid arthritis. Rheumatology, 1997, 36, 941-944.	0.9	22